Roche announced Friday that its cobas SARS-CoV-2 and A/B influenza test kits have been approved for emergency use by the U.S. Food and Drug Administration (FDA),media reported. The kit has the ability to detect and distinguish between SARS-CoV-2, Type A and Influenza B.
Thomas Schinecker, chief executive of Roche Diagnostics, said: “As the flu season approaches, this new test is particularly important because SARS-CoV-2 and flu infections are difficult to distinguish by symptoms alone. Now, with one test, healthcare professionals can safely provide patients with the right diagnosis and the most effective treatment. “
The company’s fully automated cobas 6800/8800 system can deliver up to 96 results in about 3 hours, the cobas 6800 system can provide 384 results in 8 hours and the cobas 8800 system can provide 1056 results.
The test is a multiple retroviral polymerase chain reaction (RT-PCR) test designed to detect the above virus in nasal cavity or nasopharyngeal swab samples. The test kit is also available in Europe.
Earlier this week, Roche announced that it would launch a fast antigen test for SARS-CoV-2 in Europe by the end of September. The test provides results within 15 minutes, providing the possibility to assess and treat patients more effectively.
“Detection remains an important focus in many countries,” Schinecker said. Especially during the upcoming flu season, it is important to know if a person has SARS-CoV-2 or influenza to ensure the correct treatment process. “